Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, ON / ACCESSWIRE / January 16, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ( " Intellipharmaceutics " or the " Company " ), a pharmaceutical company specializing in the research, development and manufacture of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news